<!DOCTYPE html>
<html>
    <head>
        <!-- Google tag (gtag.js) -->
        <script async src="https://www.googletagmanager.com/gtag/js?id=G-TJH2RE0DE4"></script>
        <script>
            window.dataLayer = window.dataLayer || [];
            function gtag(){dataLayer.push(arguments);}
            gtag('js', new Date());

            gtag('config', 'G-TJH2RE0DE4');
        </script>

        <title>Breast Results</title>
        <meta charset="UTF-8">
        <meta name="description" content="Breast risk results">
        <meta name="author" content="Xavier Orcutt">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
        <link rel="stylesheet" type="text/css" href="../../static/css/mystyle.css">
        <script src="../../static/scripts/myscripts.js"></script> 
    </head>
    
    <body>
        
        <!-- HEADER -->
        <header>
            <h1>Breast Results</h1>
        </header>

        <!-- <p>This patient's estimated median overall survival: <span class="med_surv_estimate"> {{ med_surv_est }} days </span></p> -->

        <p>Real-world survival estimates for therapies that could be relevant to this patient based on their biomarker status can be found below.</p>
        
        <!-- HR POSITIVE -->
        {% if bio_status == "hr_positive" %}

        <!-- HR POSITIVE: PALOMA-2 -->
        <div class="section-box">
            <p class="treatment">Palbociclib plus letrozole or letrozole in HR-positive disease</p>

            <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ paloma2_risk }} </p>
            
            {% if paloma2_risk == "Low" %}
            <p><span class="risk-benefit">Based on the patient's risk, is palbociclib plus letrozole expected to offer a survival advantage over letrozole alone?</span> Yes</p>

            <p>Click below for more information on progression free survival (PFS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/NEJMoa1607303">PALOMA-2</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">PFS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/paloma2_low.png">
                </div>
            </div>
        
            {% elif paloma2_risk == "Medium" %}
            <p><span class="risk-benefit">Based on the patient's risk, is palbociclib plus letrozole expected to offer a survival advantage over letrozole alone?</span> Yes</p>

            <p>Click below for more information on progression free survival (PFS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/NEJMoa1607303">PALOMA-2</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">PFS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/paloma2_med.png">
                </div>
            </div>
       
            {% elif paloma2_risk == "High"%}
            <p><span class="risk-benefit">Based on the patient's risk, is palbociclib plus letrozole expected to offer a survival advantage over letrozole alone?</span> No</p>

            <p>Click below for more information on progression free survival (PFS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/NEJMoa1607303">PALOMA-2</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">PFS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/paloma2_high.png">
                </div>
            </div>
            {% endif %}
        
            <div class="collapsible">
                <button class="collapsible-button">RCT comparison</button>
                <div class="content">
                  <img src="../../static/images/breast/paloma2_summary.pdf">
                </div>
            </div>
        </div>

        <div class="space-result"></div>

        <!-- HR POSITIVE: PALOMA-3 -->
        <div class="section-box">
            <p class="treatment">Palbociclib plus fulvestrant or fulvestrant in HR-positive disease</p>

            <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ paloma3_risk }} </p>
                        
            {% if paloma3_risk == "Low" %}
            <p><span class="risk-benefit">Based on the patient's risk, is palbociclib plus fulvestrant expected to offer a survival advantage over fulvestrant alone?</span> Yes</p>

            <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1810527">PALOMA-3</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">OS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/paloma3_low.png">
                </div>
            </div>
        
            {% elif paloma3_risk == "Medium" %}
            <p><span class="risk-benefit">Based on the patient's risk, is palbociclib plus fulvestrant expected to offer a survival advantage over fulvestrant alone?</span> Yes</p>

            <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1810527">PALOMA-3</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">OS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/paloma3_med.png">
                </div>
            </div>
       
            {% elif paloma3_risk == "High"%}
            <p><span class="risk-benefit">Based on the patient's risk, is palbociclib plus fulvestrant expected to offer a survival advantage over fulvestrant alone?</span> Yes</p>

            <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1810527">PALOMA-3</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">OS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/paloma3_high.png">
                </div>
            </div>
            {% endif %}
        
            <div class="collapsible">
                <button class="collapsible-button">RCT comparison</button>
                <div class="content">
                  <img src="../../static/images/breast/paloma3_summary.pdf">
                </div>
            </div>
        </div>
        {% endif %}

        <!-- HER2 POSITIVE -->
        {% if bio_status == "her2_positive" %}
        <div class="section-box">
            <p class="treatment">Pertuzumab, trastuzumab, and docetaxel or trastuzumab and docetaxel in HER2-positive disease</p>

            <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ cleopatra_risk }} </p>

            {% if cleopatra_risk == "Low" %}
            <p><span class="risk-benefit">Based on the patient's risk, is the addition of pertuzumab to trastuzumab and docetaxl expected to offer a survival advantage?</span> Yes</p>

            <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1413513">CLEOPATRA</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">OS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/cleopatra_low.png">
                </div>
            </div>

            {% elif cleopatra_risk == "Medium" %}
            <p><span class="risk-benefit">Based on the patient's risk, is the addition of pertuzumab to trastuzumab and docetaxl expected to offer a survival advantage?</span> No</p>

            <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1413513">CLEOPATRA</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">OS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/cleopatra_med.png">
                </div>
            </div>
       
            {% elif cleopatra_risk == "High"%}
            <p><span class="risk-benefit">Based on the patient's risk, is the addition of pertuzumab to trastuzumab and docetaxl expected to offer a survival advantage?</span> No</p>

            <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1413513">CLEOPATRA</a> trial:</p>
            <div class="collapsible">
                <button class="collapsible-button">OS estimate</button>
                <div class="content">
                    <img src="../../static/images/breast/cleopatra_high.png">
                </div>
            </div>
            {% endif %}

            <div class="collapsible">
                <button class="collapsible-button">RCT comparison</button>
                <div class="content">
                  <img src="../../static/images/breast/cleopatra_summary.pdf">
                </div>
            </div>
        </div>
        {% endif %}

        <!-- TRIPLE NEGATIVE -->
        {% if bio_status == 'triple_negative' %}
        <div class="section-box">
            <p class="empty">No treatment survival estimates available for patients with triple negative disease or unknown HER2 status.</p>
        </div>
        {% endif %}

        <form>
            <button class="back-button" onclick="window.location.href='/breast'">Back to form</button>
            <button class="home-button" onclick="window.location.href='/' ; return false;">Home</button>
        </form>
  
    </body>
</html>
      

